The effect of diabetes capsules on lipid profile

Evaluation of the effect of diabetes capsule (a TIM product ) consumption on lipid profile in patients with hyperlipidemia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141027019705N4

Enrollment

Registered

2020-09-24

Start date

2020-05-20

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patients with impaired lipid profile. Hyperlipidemia, unspecified

Interventions

Intervention 1: Intervention group: This group received 3 diabetic capsules (500 mg) daily for 6 weeks. Diabetes capsule consists of three plant components (Rhus corindria, Trigonella Foenum and Portu

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Not having known heart disease Having a disorder in lipid profile

Exclusion criteria

Exclusion criteria: Unwilling to enter the study Sensitivity to diabetes capsules

Design outcomes

Primary

Measure	Time frame
Improving blood LDL. Timepoint: Measurement of blood LDL in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring blood LDL using biochemical kits.;Improving blood HDL. Timepoint: Measurement of blood HDL in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring blood HDL using biochemical kits.;Improving total cholesterol. Timepoint: Measurement of total cholesterol in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring total cholesterol using biochemical kits.;Improving blood triglycerides. Timepoint: Measurement of blood triglycerides in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring blood triglycerides using biochemical kits.;Improving blood VLDL. Timepoint: Measurement of blood VLDL in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring blood VLDL using biochemical kits.	—

Measure

Time frame

Improving blood LDL. Timepoint: Measurement of blood LDL in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring blood LDL using biochemical kits.;Improving blood HDL. Timepoint: Measurement of blood HDL in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring blood HDL using biochemical kits.;Improving total cholesterol. Timepoint: Measurement of total cholesterol in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring total cholesterol using biochemical kits.;Improving blood triglycerides. Timepoint: Measurement of blood triglycerides in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring blood triglycerides using biochemical kits.;Improving blood VLDL. Timepoint: Measurement of blood VLDL in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring blood VLDL using biochemical kits.

—

Secondary

Measure	Time frame
Weight. Timepoint: Before the intervention and 6 weeks after the intervention. Method of measurement: Scales.;BMI. Timepoint: Before the intervention and 6 weeks after the intervention. Method of measurement: Weight (kg) / height (meters) to the power of 2.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Salehi

Arak University of Medical Sciences

m_salehi@razi.tums.ac.ir+98 86 3417 3645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026